Global Respiratory Syncytial Virus (RSV) Therapeutics Market - 2023-2030

Market Overview

The Global Respiratory Syncytial Virus (RSV) Therapeutics Market reached US$ 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.4 billion by 2030. The global Respiratory Syncytial Virus (RSV) therapeutics market is expected to exhibit a CAGR of 10.2% during the forecast period (2023-2030). The increasing hospital admissions and the growing clinical trialsfor novel drugs are driving up demand for respiratory syncytial virus therapeutics market trends.

Respiratory Syncytial Virus (RSV) is a common viral infection that mostly affects newborns and young children's respiratory systems. RSV can also cause serious respiratory infection in elderly people and those with compromised immune systems. RSV is the most common cause of hospitalisation among babies and young children. Effective therapies may lessen the severity of the infection, reduce the need for hospitalization, and so reduce the pressure on healthcare systems.

Market Dynamics

Rise in the Clinical Trials by the Key Players is expected to Drive the Market Growth

The increase in clinical trials by key companies is projected to fuel market growth. For instance, May 8, 2023, The China National Medical Products Administration ("NMPA") has approved a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV) infection, according to Ascletis Pharma Inc.

Based on the available results, a dose of 800 mg ASC10 twice daily was chosen for a randomised, double-blind, placebo-controlled Phase IIa research to assess the antiviral efficacy, safety, tolerability, and pharmacokinetics of ASC10 tablets in patients with mild or moderate RSV infection. Clinical trials will also increase market growth.

Strong Pipeline of Products Showing Promising Results to Propel market growth

One of the primary tactics being investigated by pharmaceutical companies in their fight against RSV is the use of monoclonal antibodies in newborns to cause passive immunisation. The pipeline items outperform Synagis and the alternative technique of vaccination pregnant moms to deliver passive immunisation to infants. Novel mechanisms, cheaper costs, and protection for the full season with a single injection, as well as instant disease prevention, are expected to boost market growth.

For instance, on April 07, 2022, the proposed acquisition expands Pfizer's infectious disease research and development capabilities by providing a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus (RSV) infections and prevent sickness through vaccination. Pfizer's unique anti-infective portfolio is being expanded, and the company's R&D, manufacturing, and commercialization expertise is being used to meet a substantial unmet demand for RSV treatments. As a result, prominent manufacturers' focus on novel medications to treat RSV will fuel market expansion.

High Cost of Disease Management will hamper the market growth.

The cost of managing RSV is high, which is expected to limit market growth. According to the NLM, Medicaid covered 61% of newborn RSVHs. Medicaid covered 51% of baby RSVH costs, paying 32% less per hospitalisation than commercial insurance. RSV therapy for infants costs $709.6 million per year, or $187 per total birth and $227 every publicly financed delivery. This factor may further hinder the global RSV market's progress.

COVID-19 Impact Analysis

The effect of COVID-19 on Respiratory Syncytial Virus (RSV) has been complicated. During the COVID-19 pandemic, RSV epidemiology and clinical patterns changed dramatically. Non-pharmaceutical approaches aimed at reducing COVID-19 transmission, including as mask use, social distancing, and improved hand hygiene, resulted in a considerable decrease in RSV cases.

The influence of COVID-19 on RSV infection has highlighted the importance of ongoing surveillance, readiness, and the development of efficient preventative and therapeutic strategies to limit the recurrence and impact of RSV infections.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global respiratory syncytial virus therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global respiratory syncytial virus therapeutics market growth over the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence is anticipated to impact the growth of global respiratory syncytial virus therapeutics market positively. AI can be used for virtual screening of large chemical libraries to identify molecules with the potential to bind to specific viral targets. By using computational models and algorithms, researchers can predict the binding affinity of thousands or millions of compounds, allowing them to identify promising candidates for further testing

Segment Analysis

The global respiratory syncytial virus therapeutics market is segmented based on drug type, dosage form, treatment type, distribution channel and region.

Hospital Pharmacy from Distribution Channel Segment Accounts for 41.3% of Market Share

Because RSV infection is common in neonates and infants, therapy for these populations must be closely monitored around the clock, resulting in a high hospitalisation rate in cases of RSV infection. RSV is more common in the winter and spring months in the United States. RSV is a virus that can be treated on an outpatient basis in the majority of children and newborns. However, between 0.5 to 2% of children and newborns with RSV may require hospitalisation.

For instance, according to CDC, RSV causes approximately 2.4 million outpatient (non-hospitalization) visits among children under the age of five in the United States each year. 60,000-90,000 hospitalisations among children under the age of five. In addition, 50,000-150,000 hospitalisations among aged 65 and older. As a result, those figures will drive the growth of the hospital pharmacy segment.

Geographical Analysis

Asia Pacific Accounted for Approximately 22.4% of the Market Share

Due to the high population density and rapidly increasing frequency of infectious disorders, the Asia Pacific respiratory syncytial virus diagnostics market is predicted to develop the fastest over the forecast period. Strong need for automated healthcare testing for accurate and faster disease diagnosis is projected to drive regional market expansion.

Due to rising healthcare systems and an increasing number of government programmes, China, India, Japan, and Malaysia are likely to be the region's fastest-growing markets. Furthermore, the expanding newborn population is likely to drive market growth.

For instance, according to TheWorldCounts, Every year, over 140 million infants are born around the world. Every second, more than four babies are born. Every year, Asia accounts for more than half of global births, with 25 million births in India and 16 million births in China alone. These indicators indicate that Asia Pacific will dominate the market.

Competitive Landscape

The major global players in the market include: Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., and mAbxience, among others.

Why Purchase the Report?

• To visualize the global respiratory syncytial virus therapeutics market segmentation based on infection type, drug type, end user and region,as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of respiratory syncytial virus therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global respiratory syncytial virus therapeutics market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies